LAVA Therapeutics N.V.

NASDAQ:LVTX

1.77 (USD) • At close November 4, 2024
Bedrijfsnaam LAVA Therapeutics N.V.
Symbool LVTX
Munteenheid USD
Prijs 1.77
Beurswaarde 46,537,194
Dividendpercentage 0%
52-weken bereik 1.16 - 6.47
Industrie Biotechnology
Sector Healthcare
CEO Mr. Stephen Allen Hurly M.B.A., M.Sc.
Website https://www.lavatherapeutics.com

An error occurred while fetching data.

Over LAVA Therapeutics N.V.

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.

Vergelijkbare Aandelen

Aeglea BioTherapeutics, Inc. logo

Aeglea BioTherapeutics, Inc.

AGLE

12.01 USD

Ardelyx, Inc. logo

Ardelyx, Inc.

ARDX

5.89 USD

DURECT Corporation logo

DURECT Corporation

DRRX

1.35 USD

Axcella Health Inc. logo

Axcella Health Inc.

AXLA

4.58 USD

iCAD, Inc. logo

iCAD, Inc.

ICAD

1.74 USD

Aptose Biosciences Inc. logo

Aptose Biosciences Inc.

APTO

0.398 USD

Trevi Therapeutics, Inc. logo

Trevi Therapeutics, Inc.

TRVI

3.04 USD

PAVmed Inc. logo

PAVmed Inc.

PAVM

1.05 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)